Letter to the Editor: clinical utility of urine DNA for noninvasive detection and minimal residual disease monitoring in urothelial carcinoma
Abstract Current methods for the early detection and minimal residual disease (MRD) monitoring of urothelial carcinoma (UC) are invasive and/or possess suboptimal sensitivity. We developed an efficient workflow named urine tumor DNA multidimensional bioinformatic predictor (utLIFE). Using UC-specifi...
| Main Authors: | , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2023-02-01
|
| Series: | Molecular Cancer |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s12943-023-01729-7 |
| _version_ | 1811171844900782080 |
|---|---|
| author | Kaiwei Yang Hailong Hu Junlong Wu Huina Wang Zhaoxia Guo Wei Yu Lin Yao Feng Ding Tao Zhou Wang Wang Yunkai Wang Lei Liu Jing Guo Shuaipeng Zhu Xinhao Zhang Shanbo Cao Feng Lou Yuanjie Niu Dingwei Ye Zhisong He |
| author_facet | Kaiwei Yang Hailong Hu Junlong Wu Huina Wang Zhaoxia Guo Wei Yu Lin Yao Feng Ding Tao Zhou Wang Wang Yunkai Wang Lei Liu Jing Guo Shuaipeng Zhu Xinhao Zhang Shanbo Cao Feng Lou Yuanjie Niu Dingwei Ye Zhisong He |
| author_sort | Kaiwei Yang |
| collection | DOAJ |
| description | Abstract Current methods for the early detection and minimal residual disease (MRD) monitoring of urothelial carcinoma (UC) are invasive and/or possess suboptimal sensitivity. We developed an efficient workflow named urine tumor DNA multidimensional bioinformatic predictor (utLIFE). Using UC-specific mutations and large copy number variations, the utLIFE-UC model was developed on a bladder cancer cohort (n = 150) and validated in The Cancer Genome Atlas (TCGA) bladder cancer cohort (n = 674) and an upper tract urothelial carcinoma (UTUC) cohort (n = 22). The utLIFE-UC model could discriminate 92.8% of UCs with 96.0% specificity and was robustly validated in the BLCA_TCGA and UTUC cohorts. Furthermore, compared to cytology, utLIFE-UC improved the sensitivity of bladder cancer detection (p < 0.01). In the MRD cohort, utLIFE-UC could distinguish 100% of patients with residual disease, showing superior sensitivity compared to cytology (p < 0.01) and fluorescence in situ hybridization (FISH, p < 0.05). This study shows that utLIFE-UC can be used to detect UC with high sensitivity and specificity in patients with early-stage cancer or MRD. The utLIFE-UC is a cost-effective, rapid, high-throughput, noninvasive, and promising approach that may reduce the burden of cystoscopy and blind surgery. |
| first_indexed | 2024-04-10T17:20:56Z |
| format | Article |
| id | doaj.art-c84f7d7d90684ce0b97ac947c17fe31b |
| institution | Directory Open Access Journal |
| issn | 1476-4598 |
| language | English |
| last_indexed | 2024-04-10T17:20:56Z |
| publishDate | 2023-02-01 |
| publisher | BMC |
| record_format | Article |
| series | Molecular Cancer |
| spelling | doaj.art-c84f7d7d90684ce0b97ac947c17fe31b2023-02-05T12:06:11ZengBMCMolecular Cancer1476-45982023-02-012211710.1186/s12943-023-01729-7Letter to the Editor: clinical utility of urine DNA for noninvasive detection and minimal residual disease monitoring in urothelial carcinomaKaiwei Yang0Hailong Hu1Junlong Wu2Huina Wang3Zhaoxia Guo4Wei Yu5Lin Yao6Feng Ding7Tao Zhou8Wang Wang9Yunkai Wang10Lei Liu11Jing Guo12Shuaipeng Zhu13Xinhao Zhang14Shanbo Cao15Feng Lou16Yuanjie Niu17Dingwei Ye18Zhisong He19Department of Urology, Peking University First HospitalDepartment of Urology, The Second Affiliated Hospital of Tianjin Medical UniversityDepartment of Urology, Fudan University Shanghai Cancer CenterAcornmed Biotechnology Co., LtdAcornmed Biotechnology Co., LtdDepartment of Urology, Peking University First HospitalDepartment of Urology, Peking University First HospitalAcornmed Biotechnology Co., LtdAcornmed Biotechnology Co., LtdAcornmed Biotechnology Co., LtdAcornmed Biotechnology Co., LtdAcornmed Biotechnology Co., LtdAcornmed Biotechnology Co., LtdAcornmed Biotechnology Co., LtdAcornmed Biotechnology Co., LtdAcornmed Biotechnology Co., LtdAcornmed Biotechnology Co., LtdDepartment of Urology, The Second Affiliated Hospital of Tianjin Medical UniversityDepartment of Urology, Fudan University Shanghai Cancer CenterDepartment of Urology, Peking University First HospitalAbstract Current methods for the early detection and minimal residual disease (MRD) monitoring of urothelial carcinoma (UC) are invasive and/or possess suboptimal sensitivity. We developed an efficient workflow named urine tumor DNA multidimensional bioinformatic predictor (utLIFE). Using UC-specific mutations and large copy number variations, the utLIFE-UC model was developed on a bladder cancer cohort (n = 150) and validated in The Cancer Genome Atlas (TCGA) bladder cancer cohort (n = 674) and an upper tract urothelial carcinoma (UTUC) cohort (n = 22). The utLIFE-UC model could discriminate 92.8% of UCs with 96.0% specificity and was robustly validated in the BLCA_TCGA and UTUC cohorts. Furthermore, compared to cytology, utLIFE-UC improved the sensitivity of bladder cancer detection (p < 0.01). In the MRD cohort, utLIFE-UC could distinguish 100% of patients with residual disease, showing superior sensitivity compared to cytology (p < 0.01) and fluorescence in situ hybridization (FISH, p < 0.05). This study shows that utLIFE-UC can be used to detect UC with high sensitivity and specificity in patients with early-stage cancer or MRD. The utLIFE-UC is a cost-effective, rapid, high-throughput, noninvasive, and promising approach that may reduce the burden of cystoscopy and blind surgery.https://doi.org/10.1186/s12943-023-01729-7Urothelial carcinomaUrine DNAutLIFEEarly detectionMRD |
| spellingShingle | Kaiwei Yang Hailong Hu Junlong Wu Huina Wang Zhaoxia Guo Wei Yu Lin Yao Feng Ding Tao Zhou Wang Wang Yunkai Wang Lei Liu Jing Guo Shuaipeng Zhu Xinhao Zhang Shanbo Cao Feng Lou Yuanjie Niu Dingwei Ye Zhisong He Letter to the Editor: clinical utility of urine DNA for noninvasive detection and minimal residual disease monitoring in urothelial carcinoma Molecular Cancer Urothelial carcinoma Urine DNA utLIFE Early detection MRD |
| title | Letter to the Editor: clinical utility of urine DNA for noninvasive detection and minimal residual disease monitoring in urothelial carcinoma |
| title_full | Letter to the Editor: clinical utility of urine DNA for noninvasive detection and minimal residual disease monitoring in urothelial carcinoma |
| title_fullStr | Letter to the Editor: clinical utility of urine DNA for noninvasive detection and minimal residual disease monitoring in urothelial carcinoma |
| title_full_unstemmed | Letter to the Editor: clinical utility of urine DNA for noninvasive detection and minimal residual disease monitoring in urothelial carcinoma |
| title_short | Letter to the Editor: clinical utility of urine DNA for noninvasive detection and minimal residual disease monitoring in urothelial carcinoma |
| title_sort | letter to the editor clinical utility of urine dna for noninvasive detection and minimal residual disease monitoring in urothelial carcinoma |
| topic | Urothelial carcinoma Urine DNA utLIFE Early detection MRD |
| url | https://doi.org/10.1186/s12943-023-01729-7 |
| work_keys_str_mv | AT kaiweiyang lettertotheeditorclinicalutilityofurinednafornoninvasivedetectionandminimalresidualdiseasemonitoringinurothelialcarcinoma AT hailonghu lettertotheeditorclinicalutilityofurinednafornoninvasivedetectionandminimalresidualdiseasemonitoringinurothelialcarcinoma AT junlongwu lettertotheeditorclinicalutilityofurinednafornoninvasivedetectionandminimalresidualdiseasemonitoringinurothelialcarcinoma AT huinawang lettertotheeditorclinicalutilityofurinednafornoninvasivedetectionandminimalresidualdiseasemonitoringinurothelialcarcinoma AT zhaoxiaguo lettertotheeditorclinicalutilityofurinednafornoninvasivedetectionandminimalresidualdiseasemonitoringinurothelialcarcinoma AT weiyu lettertotheeditorclinicalutilityofurinednafornoninvasivedetectionandminimalresidualdiseasemonitoringinurothelialcarcinoma AT linyao lettertotheeditorclinicalutilityofurinednafornoninvasivedetectionandminimalresidualdiseasemonitoringinurothelialcarcinoma AT fengding lettertotheeditorclinicalutilityofurinednafornoninvasivedetectionandminimalresidualdiseasemonitoringinurothelialcarcinoma AT taozhou lettertotheeditorclinicalutilityofurinednafornoninvasivedetectionandminimalresidualdiseasemonitoringinurothelialcarcinoma AT wangwang lettertotheeditorclinicalutilityofurinednafornoninvasivedetectionandminimalresidualdiseasemonitoringinurothelialcarcinoma AT yunkaiwang lettertotheeditorclinicalutilityofurinednafornoninvasivedetectionandminimalresidualdiseasemonitoringinurothelialcarcinoma AT leiliu lettertotheeditorclinicalutilityofurinednafornoninvasivedetectionandminimalresidualdiseasemonitoringinurothelialcarcinoma AT jingguo lettertotheeditorclinicalutilityofurinednafornoninvasivedetectionandminimalresidualdiseasemonitoringinurothelialcarcinoma AT shuaipengzhu lettertotheeditorclinicalutilityofurinednafornoninvasivedetectionandminimalresidualdiseasemonitoringinurothelialcarcinoma AT xinhaozhang lettertotheeditorclinicalutilityofurinednafornoninvasivedetectionandminimalresidualdiseasemonitoringinurothelialcarcinoma AT shanbocao lettertotheeditorclinicalutilityofurinednafornoninvasivedetectionandminimalresidualdiseasemonitoringinurothelialcarcinoma AT fenglou lettertotheeditorclinicalutilityofurinednafornoninvasivedetectionandminimalresidualdiseasemonitoringinurothelialcarcinoma AT yuanjieniu lettertotheeditorclinicalutilityofurinednafornoninvasivedetectionandminimalresidualdiseasemonitoringinurothelialcarcinoma AT dingweiye lettertotheeditorclinicalutilityofurinednafornoninvasivedetectionandminimalresidualdiseasemonitoringinurothelialcarcinoma AT zhisonghe lettertotheeditorclinicalutilityofurinednafornoninvasivedetectionandminimalresidualdiseasemonitoringinurothelialcarcinoma |